Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.